ARTICLE | Clinical News
HE2000: Began Phase I/II trial
March 15, 1999 8:00 AM UTC
Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Product: HE2000 Business: Infectious diseases Therapeutic category: Immune stimulation, Viral replication Target: Host cell factors including...